Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 123

1.

Urine steroid metabolomics as a biomarker tool for detecting malignancy in adrenal tumors.

Arlt W, Biehl M, Taylor AE, Hahner S, Libé R, Hughes BA, Schneider P, Smith DJ, Stiekema H, Krone N, Porfiri E, Opocher G, Bertherat J, Mantero F, Allolio B, Terzolo M, Nightingale P, Shackleton CH, Bertagna X, Fassnacht M, Stewart PM.

J Clin Endocrinol Metab. 2011 Dec;96(12):3775-84. doi: 10.1210/jc.2011-1565. Epub 2011 Sep 14.

2.

High diagnostic and prognostic value of steroidogenic factor-1 expression in adrenal tumors.

Sbiera S, Schmull S, Assie G, Voelker HU, Kraus L, Beyer M, Ragazzon B, Beuschlein F, Willenberg HS, Hahner S, Saeger W, Bertherat J, Allolio B, Fassnacht M.

J Clin Endocrinol Metab. 2010 Oct;95(10):E161-71. doi: 10.1210/jc.2010-0653. Epub 2010 Jul 21.

PMID:
20660055
3.

Serum inhibin pro-αC is a tumor marker for adrenocortical carcinomas.

Hofland J, Feelders RA, van der Wal R, Kerstens MN, Haak HR, de Herder WW, de Jong FH.

Eur J Endocrinol. 2012 Feb;166(2):281-9. doi: 10.1530/EJE-11-0693. Epub 2011 Nov 29.

4.

Use of urinary steroid profiling for diagnosing and monitoring adrenocortical tumours.

Tiu SC, Chan AO, Taylor NF, Lee CY, Loung PY, Choi CH, Shek CC.

Hong Kong Med J. 2009 Dec;15(6):463-70.

5.

[Clinicopathologic features and expression of epidermal growth factor receptor and vascular endothelial growth factor in adrenocortical tumors].

Wang CP, Zhang J, Gao J, Liu PP, Wu SF, Zeng X, Liang ZY.

Zhonghua Bing Li Xue Za Zhi. 2012 Oct;41(10):686-90. doi: 10.3760/cma.j.issn.0529-5807.2012.10.009. Chinese.

PMID:
23302311
6.

Diagnostic Value of Urinary Steroid Profiling in the Evaluation of Adrenal Tumors.

Kerkhofs TM, Kerstens MN, Kema IP, Willems TP, Haak HR.

Horm Cancer. 2015 Aug;6(4):168-75. doi: 10.1007/s12672-015-0224-3. Epub 2015 May 19.

7.

5th International ACC Symposium: Imaging for Diagnosis and Surveillance of Adrenal Tumors--New Advances and Reviews of Old Concepts.

Hahner S, Caoili E, Else T.

Horm Cancer. 2016 Feb;7(1):40-3. doi: 10.1007/s12672-015-0245-y. Epub 2015 Dec 18. Review.

PMID:
26684644
8.

MiR-34a and miR-483-5p are candidate serum biomarkers for adrenocortical tumors.

Patel D, Boufraqech M, Jain M, Zhang L, He M, Gesuwan K, Gulati N, Nilubol N, Fojo T, Kebebew E.

Surgery. 2013 Dec;154(6):1224-8; discussion 1229. doi: 10.1016/j.surg.2013.06.022.

9.

Adrenocortical adenomas with regression and myelolipomatous changes: urinary steroid profiling supports a distinctive benign neoplasm.

Perna V, Taylor NF, Dworakowska D, Schulte KM, Aylwin S, Al-Hashimi F, Diaz-Cano SJ.

Clin Endocrinol (Oxf). 2014 Sep;81(3):343-9. doi: 10.1111/cen.12458. Epub 2014 May 6.

PMID:
24712713
10.

Weiss criteria in large adrenocortical tumors: a validation study.

Jain M, Kapoor S, Mishra A, Gupta S, Agarwal A.

Indian J Pathol Microbiol. 2010 Apr-Jun;53(2):222-6. doi: 10.4103/0377-4929.64325.

11.

Detection of circulating tumor cells in patients with adrenocortical carcinoma: a monocentric preliminary study.

Pinzani P, Scatena C, Salvianti F, Corsini E, Canu L, Poli G, Paglierani M, Piccini V, Pazzagli M, Nesi G, Mannelli M, Luconi M.

J Clin Endocrinol Metab. 2013 Sep;98(9):3731-8. doi: 10.1210/jc.2013-1396. Epub 2013 Jul 8.

PMID:
23836937
12.
13.

Survivin in adrenocortical tumors - pathophysiological implications and therapeutic potential.

Sbiera S, Kroiss M, Thamm T, Beyer M, Majidi F, Kuehner D, Wobser M, Becker JC, Adam P, Ronchi C, Allolio B, Fassnacht M.

Horm Metab Res. 2013 Feb;45(2):137-46. doi: 10.1055/s-0032-1327750. Epub 2012 Nov 9.

PMID:
23143666
14.

Case studies in hypertension. Adrenal carcinoma.

Handler J.

J Clin Hypertens (Greenwich). 2003 Sep-Oct;5(5):355-8. No abstract available.

15.

A mimic of sarcomatoid adrenal cortical carcinoma: epithelioid angiosarcoma occurring in adrenal cortical adenoma.

Hayashi T, Gucer H, Mete O.

Endocr Pathol. 2014 Dec;25(4):404-9. doi: 10.1007/s12022-014-9330-y.

PMID:
25246132
16.

The molecular basis of adrenocortical cancer.

Lehmann T, Wrzesinski T.

Cancer Genet. 2012 Apr;205(4):131-7. doi: 10.1016/j.cancergen.2012.02.009. Review.

PMID:
22559973
17.

Histologic criteria for adrenocortical proliferative lesions: value of mitotic figure variability.

Blanes A, Diaz-Cano SJ.

Am J Clin Pathol. 2007 Mar;127(3):398-408.

PMID:
17276949
18.

Mitotane therapy in adrenocortical cancer induces CYP3A4 and inhibits 5α-reductase, explaining the need for personalized glucocorticoid and androgen replacement.

Chortis V, Taylor AE, Schneider P, Tomlinson JW, Hughes BA, O'Neil DM, Libé R, Allolio B, Bertagna X, Bertherat J, Beuschlein F, Fassnacht M, Karavitaki N, Mannelli M, Mantero F, Opocher G, Porfiri E, Quinkler M, Sherlock M, Terzolo M, Nightingale P, Shackleton CH, Stewart PM, Hahner S, Arlt W.

J Clin Endocrinol Metab. 2013 Jan;98(1):161-71. doi: 10.1210/jc.2012-2851. Epub 2012 Nov 16.

PMID:
23162091
19.

Does tumor heterogeneity limit the use of the Weiss criteria in the evaluation of adrenocortical tumors?

Pohlink C, Tannapfe A, Eichfeld U, Schmidt F, Führer D, Paschke R, Koch CA.

J Endocrinol Invest. 2004 Jun;27(6):565-9.

PMID:
15717655
20.

Analysis of circulating microRNAs in adrenocortical tumors.

Szabó DR, Luconi M, Szabó PM, Tóth M, Szücs N, Horányi J, Nagy Z, Mannelli M, Patócs A, Rácz K, Igaz P.

Lab Invest. 2014 Mar;94(3):331-9. doi: 10.1038/labinvest.2013.148. Epub 2013 Dec 16.

Supplemental Content

Support Center